Naperville, IL -- (SBWIRE) -- 09/06/2013 -- Reportstack, provider of premium market research reports announces the addition of Obesity - Pipeline Review, H2 2013 market report to its offering
Obesity - Pipeline Review, H2 2013
, 'Obesity - Pipeline Review, H2 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Obesity, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Obesity. Obesity - Pipeline Review, Half Year is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by team.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
- A snapshot of the global therapeutic scenario for Obesity.
- A review of the Obesity products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Obesity pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.
Reasons to buy
- Identify and understand important and diverse types of therapeutics under development for Obesity.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Obesity pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Boehringer Ingelheim GmbH
Shionogi & Co., Ltd.
Eli Lilly and Company
Isis Pharmaceuticals, Inc.
Merck & Co., Inc.
Novo Nordisk A/S
Takeda Pharmaceutical Company Limited
Chong Kun Dang Pharmaceutical
Glenmark Pharmaceuticals Ltd.
Kissei Pharmaceutical Co., Ltd.
Mitsubishi Tanabe Pharma Corporation
Zydus Cadila Healthcare Limited
Arrowhead Research Corporation
Ligand Pharmaceuticals Incorporated
PROLOR Biotech, Inc.
Orchid Chemicals & Pharmaceuticals Ltd
Corcept Therapeutics Incorporated
Arena Pharmaceuticals, Inc.
WhanIn Pharmaceutical Co., Ltd.
Unigene Laboratories, Inc.
Bukwang Pharmaceutical Co., Ltd.
LG Life Sciences, Ltd
Transition Therapeutics Inc.
Suven Life Sciences Ltd.
Phynova Group Ltd
Orexigen Therapeutics, Inc.
NeuroVive Pharmaceutical AB
Digna Biotech, S.L.
Sirtris Pharmaceuticals, Inc.
Jenrin Discovery, Inc.
Upsher-Smith Laboratories, Inc.
Helsinn Healthcare S.A.
Xenon Pharmaceuticals Inc.
Ocera Therapeutics, Inc.
Aileron Therapeutics, Inc.
Global Health Ventures Inc.
Braasch Biotech LLC
Zealand Pharma A/S
Indus Biotech Private Limited
Intarcia Therapeutics, Inc.
Kainos Medicine, Inc.
Avaxia Biologics, Inc.
Aegis Therapeutics, LLC
BRIDGE BIORESEARCH PLC
Molecular Design International, Inc.
N-Gene Research Laboratories, Inc.
Verva Pharmaceuticals Limited
Regulus Therapeutics Inc.
Esperion Therapeutics, Inc.
Motif BioSciences, Inc.
Sirona Biochem Corp
Vicore Pharma AB
Reviva Pharmaceuticals Inc.
To view the table of contents for this market research report please visit